<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151218">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01738789</url>
  </required_header>
  <id_info>
    <org_study_id>SIFEM-2013-1</org_study_id>
    <nct_id>NCT01738789</nct_id>
  </id_info>
  <brief_title>EURAD-MR Classification : European Multicenter Study</brief_title>
  <acronym>EURAD</acronym>
  <official_title>European Multicenter Validation of an ADNEXMR SCORING System for Characterizing Adnexal Masses: &quot;EURAD-MR Classification&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Société d'Imagerie de la Femme</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Société d'Imagerie de la Femme</source>
  <oversight_info>
    <authority>France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An adnexal mass is the most common indication for gynaecological surgery . Pre operative
      characterization is crucial and a scoring system would be useful to standardize the imaging
      report and thus, improve patient management. Recently, our center developed the first MR
      scoring system named ADNEXMR SCORING system in a retrospective study which is accurate and
      reproducible (1). Our objectives are to perform an external prospective validation of this
      scoring system, to evaluate its potential impact on therapeutic strategy and to test its
      reproducibility.

      This is a prospective large multicenter study. All patients with a sonographically
      indeterminate  adnexal mass referred for MR imaging will be consecutively included in each
      center. Then, patients will undergo a routine pelvic MR imaging. Prospectively, one senior
      and one junior radiologists independently analyze the different MR criteria to characterize
      adnexal masses.  The MR report will be issued as standard and the patient will be managed
      accordingly.  Then, the reader will classify the mass using ADNEXMR SCORING system. The
      classification will be compared to the reference standard as defined below. The
      reproducibility of the classification will be tested between the junior and the senior
      radiologist. After anonymisation, images will be analyzed by another senior radiologist of
      another center blinded from any clinical or ultrasonographical data and correlated with the
      reference standard.

      Reference standard: Reference standard will be surgical procedure with histology or standard
      clinical follow-up depending on most appropriate routine practice.

      Sample size: The sample size was computed to ensure a power of at least 90% (with a
      two-sided type I error rate of 5%) to conclude that SCORE 2 and 3 and SCORE 4 and 5 would
      have a different PPV. It would thus be necessary to have at least 569 patients classified as
      SCORE 2, 259 as SCORE 3, 52 as SCORE 4 and 51 as SCORE 5 (18). Given the prevalences, and
      assuming 6% of patients would be classified, as SCORE 1 and 10% would be lost to follow-up,
      1340 patients will be included in this study to insure a probability of at least 95% to
      obtain the aforementioned number of patients in each score category.  The inclusion period
      will last 18 months and monitoring will continue for 2 years.

      Thomassin-Naggara I., et al. Development and preliminary validation of an MRI Scoring system
      for Adnexal Masses. Radiology 2013, May;267(2):432-43.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with an indeterminate ultrasonographically adnexal mass referred for MR imaging
      will be consecutively included in each center.

      Inclusion Criteria

        -  Patient ≥ 18 years old

        -  With indeterminate ultrasonographic adnexal mass

        -  Informed consent

      Non inclusion Criteria

        -  Pregnant women

        -  Pacemaker, ferromagnetic materials, or foreign body at risk of mobilization

        -  Intolerance to iodinated or gadolinium contrast agents, or severe renal insufficiency
           (GFR &lt;30 ml/min/1.73m²).

      Objectives • Primary objective: Evaluate if ADNEXMR SCORING system is relevant for reporting
      pelvic magnetic resonance imaging (MRI) examinations performed for characterization of
      sonographically indeterminate adnexal masses in an external prospective multicenter study

      • Secondary objectives and endpoints: Evaluate

        1. The potential impact of applying the score to the therapeutic strategy, in particular
           to measure the possible reduction in oncologic surgery in benign cases

        2. If  ADNEXMR SCORING system improves reproducibility of MR report for characterization
           of adnexal masses

        3. If  ADNEXMR SCORING system is as accurate if the radiologist is blinded from any
           clinical and ultrasonographic data

      Main endpoint Joint analysis of true negative and false negative rates according to ADNEXMR
      SCORING system as compared to the histological results (or follow-up outcome, see &quot;reference
      standard&quot;, below) with an evaluation of the sensitivity and the specificity of the score
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>External validation of Adnex MR scoring system</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate if ADNEXMR SCORING system is relevant for reporting pelvic magnetic resonance imaging (MRI) examinations performed for characterization of sonographically indeterminate adnexal masses in an external prospective multicenter study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Potential reduction of unnecessary surgery</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The potential impact of applying the score to the therapeutic strategy, in particular to measure the possible reduction in unnecessary surgery in benign cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of the score</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>If  ADNEXMR SCORING system improves reproducibility of MR report for characterization of adnexal masses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between a blinded and an unblinded radiologist regarding sonographic data</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>If  ADNEXMR SCORING system is as accurate if the radiologist is blinded from any clinical and ultrasonographic data</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1340</enrollment>
  <condition>Ovarian Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with a sonographically indeterminate adnexal mass referred for MR imaging
        will be consecutively included in each center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patient ≥ 18 years old

          -  With sonographically indeterminate adnexal mass

          -  Informed consent

        Exclusion Criteria

          -  Pregnant women (relative contra indication for gadolinium injection)

          -  Pacemaker, ferromagnetic materials, or foreign body at risk of mobilization or any
             other contra-indication to MR imaging.

          -  Intolerance to iodinated or gadolinium contrast agents, or severe renal insufficiency
             (GFR &lt;30 ml/min/1.73m²).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Thomassin-Naggara, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique des Hopitaux de Paris, Université Pierre et Marie Curie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Rockall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College of London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Bazot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Thomassin-Naggara, MD, PhD</last_name>
    <phone>0156016453</phone>
    <email>isabelle.thomassin@tnn.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Institute of Radiology</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemarie Forstner</last_name>
      <email>R.Forstner@salk.at</email>
    </contact>
    <investigator>
      <last_name>Rosemarie Forstner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain Thille, MD</last_name>
      <email>alain@thille.be</email>
    </contact>
    <investigator>
      <last_name>Alain Thille</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Dubrav</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>I Giordana</last_name>
      <email>gordana.augustan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>I Giordana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Taieb, MD</last_name>
      <email>S-Taieb@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Taeib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc Ceugnart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corinne Jumelle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie Jalaguier, MD</last_name>
      <email>aureliejalaguier@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Aurélie Jalaguier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Juhan, MD</last_name>
      <email>Valerie.JUHAN@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Valerie Juhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale Siles, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Taourel, MD</last_name>
      <email>patricetaourel@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice Taourel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingrid Millet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tenon Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Thomassin-Naggara, MD, PhD</last_name>
      <phone>0663067321</phone>
      <email>isabellethomassin@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Thomassin-Naggara, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Bazot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Bendavid, MD</last_name>
      <email>sandrabendavid@free.fr</email>
    </contact>
    <investigator>
      <last_name>Sandra Bendavid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine Sebbag, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Huguenin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene Berment, MD</last_name>
      <email>helene.berment@curie.net</email>
    </contact>
    <investigator>
      <last_name>Helene Berment, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Malhaire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Lucidarme, MD, PhD</last_name>
      <email>olivier.lucidarme@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Olivier Lucidarme, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yasmina Badachi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure Fournier, MD, PhD</last_name>
      <email>laure.fournier@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Laure Fournier, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Foucauld Chamming's, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre imagerie Pyramides</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Perrot, MD</last_name>
      <email>vitenson@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Perrot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Frey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine Ribeiro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard Poncelet, MD</last_name>
      <email>poncelet.edouard@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Edouard Poncelet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Balleyguier, MD</last_name>
      <email>balleyguier@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Corinne Balleyguier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Canale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Paul Catholic University</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>G Reistano</last_name>
      <email>grestaino@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>G Reistano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Umberto I hospital Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>G Masseli</last_name>
      <email>g.masselli@policlinicoumberto1.it</email>
    </contact>
    <investigator>
      <last_name>G Masseli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto di Radiologia</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Pozzi-Mucelli</last_name>
      <email>roberto.pozzimucelli@uniivr.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Pozzi-Mucelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Riccardo Manfredi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Portuges de Oncologia de Lisboa Francisco Gentil</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Margarida Cunha</last_name>
      <email>tmargarida@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Teresa Margarida Cunha</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>C Campos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital da Luz</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldagisa Guerra</last_name>
      <email>gisaguerra@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gisa Guerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Vojvodine</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanja Stojanovic</last_name>
      <email>tupsons@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sanja Stojanovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hodpital Dubrav</name>
      <address>
        <city>Baden</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rahel Kubik</last_name>
      <email>Rahel.Kubik@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Rahel Kubik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique des grangettes</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Kinkel</last_name>
      <email>karen.kinkel-trugli@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Karen Kinkel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrokes hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzan Freeman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Susan Freeman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Rockall, MD</last_name>
      <email>a.rockall@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Andrea Rockall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nishat Bharwani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M Hall-Craggs, MD</last_name>
    </contact>
    <investigator>
      <last_name>M Hall-Craggs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anju Sahdev</last_name>
      <email>Anju.Sahdev@bartshealth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anju Sahdev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Steeping Hill hospital</name>
      <address>
        <city>Stockport</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maryna Lewinski</last_name>
      <email>Maryna.Lewinski@stockport.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Maryna Lewinski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Serbia</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 25, 2013</lastchanged_date>
  <firstreceived_date>November 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Société d'Imagerie de la Femme</investigator_affiliation>
    <investigator_full_name>Isabelle Thomassin-Naggara</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Adnexal masses</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Ovarian tumor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
